Patient value: Perspectives from the advocacy community

被引:28
作者
Addario, Bonnie J. [1 ]
Fadich, Ana [2 ]
Fox, Jesme [3 ]
Krebs, Linda [4 ]
Maskens, Deborah [5 ]
Oliver, Kathy [6 ]
Schwartz, Erin [7 ]
Spurrier-Bernard, Gilliosa [8 ]
Turnham, Timothy [9 ]
机构
[1] Bonnie J Addario Lung Canc Fdn ALCF, San Carlos, CA USA
[2] Mens Hlth Network, Washington, DC USA
[3] Roy Castle Lung Canc Fdn, Liverpool, Merseyside, England
[4] Int Soc Nurses Canc Care, Vancouver, BC, Canada
[5] Kidney Canc Canada, IKCC, Guelph, ON, Canada
[6] IBTA, Surrey, England
[7] Max Fdn, Strateg Partnerships & Commun, Seattle, WA USA
[8] Melanoma France, Teilhet, France
[9] Melanoma Res Fdn, Washington, DC USA
关键词
patient-derived preferences; patient-relevant values; patient-reported outcomes; value frameworks; CELL LUNG-CANCER; TREATMENT DECISION-MAKING; HEALTH-CARE; PATIENTS PREFERENCES; PRACTICE GUIDELINES; BREAST-CANCER; VALUE FRAMEWORK; INFORMATION; PHYSICIAN; INVOLVEMENT;
D O I
10.1111/hex.12628
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
100404 [儿少卫生与妇幼保健学];
摘要
All health-care systems are under financial pressure and many have therefore developed value frameworks to assist decision making regarding access to treatment. Unfortunately, many frameworks simply reflect the clinically focused values held by health-care professionals rather than outcomes that also matter to patients. It is difficult to define one single homogeneous set of patient values as these are shaped by social, religious and cultural factors, and health-care environment, as well as many factors such as age, gender, education, family and friends and personal finances. Instead of focusing on an aggregated set of values, frameworks should attempt to incorporate the broader range of outcomes that patients may regard as more relevant. Patient advocates are well placed to advise assessment bodies on how particular therapies will impact the patient population under consideration and should be closely involved in developing value frameworks. In this paper, a group of patient advocates explore the varying definitions of patient value and make positive recommendations for working together to strengthen the patient voice in this area. The authors call on framework developers, the patient advocacy and research communities, the health-care industry and decision-makers to undertake specific actions to ensure patient value is included in current and future value frameworks. This is justified on compassionate and economic grounds: better health outcomes result when patients receive treatment tailored to individual needs. Paying attention to the patient perspective also results in better use of resourcesa goal that should appeal to all stakeholders.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 46 条
[1]
Patients' preferences within randomised trials: systematic review and patient level meta-analysis [J].
Adamson, Simon J. ;
Bland, J. Martin ;
Hay, Elaine M. ;
Johnson, Ruth E. ;
Jones, Gareth T. ;
Kitchener, Henry ;
Moffett, Jennifer A. Klaber ;
Macfarlane, Gary J. ;
MacPherson, Hugh ;
McLean, Sionnadh ;
Nelson, Linsey ;
Salisbury, Chris ;
Thomas, Elaine ;
Tilbrook, Helen E. ;
Torgerson, David J. .
BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 :85-87
[2]
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines [J].
Anderson, Jeffrey L. ;
Heidenreich, Paul A. ;
Barnett, Paul G. ;
Creager, Mark A. ;
Fonarow, Gregg C. ;
Gibbons, Raymond J. ;
Halperin, Jonathan L. ;
Hlatky, Mark A. ;
Jacobs, Alice K. ;
Mark, Daniel B. ;
Masoudi, Frederick A. ;
Peterson, Eric D. ;
Shaw, Leslee J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (21) :2304-2322
[3]
[Anonymous], EV VAL NEW DRUGS DEV
[4]
ETHNICITY AND ATTITUDES TOWARD PATIENT AUTONOMY [J].
BLACKHALL, LJ ;
MURPHY, ST ;
FRANK, G ;
MICHEL, V ;
AZEN, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (10) :820-825
[5]
Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review [J].
Blinman, Prunella ;
Alam, Mahmood ;
Duric, Vlatka ;
McLachlan, Sue-Anne ;
Stockler, Martin R. .
LUNG CANCER, 2010, 69 (02) :141-147
[6]
Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis [J].
Bridges, John F. P. ;
Mohamed, Ateesha F. ;
Finnern, Henrik W. ;
Woehl, Anette ;
Hauber, A. Brett .
LUNG CANCER, 2012, 77 (01) :224-231
[7]
Patient preferences versus physician perceptions of treatment decisions in cancer care [J].
Bruera, E ;
Sweeney, C ;
Calder, K ;
Palmer, L ;
Benisch-Tolley, S .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2883-2885
[8]
Trading treatment toxicity for survival in locally advanced non-small cell lung cancer [J].
Brundage, MD ;
Davidson, JR ;
Mackillop, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :330-340
[9]
Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support [J].
Brundage, MD ;
Feldman-Stewart, D ;
Cosby, R ;
Gregg, R ;
Dixon, P ;
Youssef, Y ;
Mackillop, WJ .
PATIENT EDUCATION AND COUNSELING, 2001, 45 (02) :149-157
[10]
The dynamics of change: Cancer patients' preferences for information, involvement and support [J].
Butow, PN ;
Maclean, M ;
Dunn, SM ;
Tattersall, MHN ;
Boyer, MJ .
ANNALS OF ONCOLOGY, 1997, 8 (09) :857-863